Bristol Myers Squibb Announces New Data from the Long-Term D

Sustained efficacy was confirmed with an annualized relapse rate of 0.098 and 67% of patients were relapse-free at six years


Safety was consistent with prior findings and the established safety...

Related Keywords

West Palm Beach , Florida , United States , Jennifer Hadlock , Damemarie Paul , John Deluca , Bristol Myers Squibb , Bruce Cree , Krzysztof Selmaj , Hans Peter Hartung , Jonathan Sadeh , Diego Centonze , Exchange Commission , Weill Institute For Neurosciences , Research In Multiple Sclerosis , Facebook , University Of California San Francisco , Twitter , Ucsf Ms Center , Instagram , Americas Committee For Treatment , Youtube , Clinical Research , Linkedin , Americas Committee , Multiple Sclerosis , Clinical Neurology , California San Francisco , Weill Institute , Clinical Research Director , Bristol Myers , Myers Squibb , Ralf Gold , Sarah Morrow , Delivering Breakthrough Science , Meaningful Interventions , Multifocal Leukoencephalopathy , Atrioventricular Conduction Delays , Blood Pressure , Reversible Encephalopathy Syndrome , Immune Modulating Drugs , Disability After Stopping , Common Adverse Reactions , Specific Populations , Hepatic Impairment , Prescribing Information , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports ,